Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

RARE

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-15Shares Purchased (TTM):0Shares Sold (TTM):140,830

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:93,566,809Shares Outstanding:100,600,000Institutional Ownership Pct.:93.01%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	125	175	421	203	176	127	174	151	481	112	214	73
Available For Sale Securities Debt Securities Curr…	167	238	259	223	311	367	436	471	283	300	364	370
Accounts Receivable Net Current	200	121	158	113	124	99	122	93	106	100	73	79
Inventory Net	59	55	52	52	46	46	45	43	40	36	34	32
Other Assets Current	-	-	-	-	-	-	-	41	55	48	48	-
Prepaid Expense And Other Assets Current	55	68	61	53	61	60	40	-	-	-	48	46
Assets Current	606	657	951	643	720	699	817	800	965	596	732	599
Property Plant And Equipment Net	235	239	244	250	256	261	266	272	279	285	291	297
Available For Sale Securities Debt Securities Nonc…	144	121	57	22	51	69	135	203	111	157	200	82
Operating Lease Right Of Use Asset	-	-	-	-	-	-	-	-	-	-	-	26
Intangible Assets Net Excluding Goodwill	172	174	176	173	175	177	178	165	166	165	166	157
Goodwill	44	44	44	44	44	44	44	44	44	44	44	44
Other Assets Noncurrent	63	61	60	58	60	62	63	54	54	60	58	28
Assets	1,264	1,296	1,532	1,190	1,306	1,312	1,503	1,538	1,618	1,307	1,491	1,238
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	39	42	31	41	34	47	39	36	60	41	42	33
Accrued Liabilities Current	221	194	265	221	181	173	241	185	154	149	196	179
Operating Lease Liability Current	-	-	12	12	12	10	10	-	-	-	13	-
Other Liabilities Current	15	17	7	1	3	3	4	5	-	-	0	-
Liabilities Current	351	325	384	340	293	292	344	285	273	246	280	254
Operating Lease Liability Noncurrent	-	-	24	22	25	28	30	-	-	-	31	-
Deferred Income Tax Liabilities Net	30	30	30	30	30	30	30	30	30	30	30	32
Other Liabilities Noncurrent	41	42	20	19	17	17	17	16	15	14	12	10
Liabilities	1,548	1,525	1,605	1,174	1,148	1,161	1,241	1,185	1,186	1,167	1,216	1,206
Temporary Equity Carrying Amount Including Portion…	7	7	7	7	7	7	7	7	-	-	0	-
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Treasury Stock Value	-10	-10	-8	-8	-8	-8	-4	-4	-3	-3	-0	-0
Treasury Stock Deferred Employee Stock Ownership P…	10	10	8	8	8	8	4	4	3	3	0	0
Additional Paid In Capital	4,518	4,481	4,451	4,412	4,374	4,252	4,213	4,169	4,123	3,699	3,662	3,298
Accumulated Other Comprehensive Income Loss Net Of…	0	0	1	1	-0	-0	-1	1	-1	-0	1	-2
Retained Earnings Accumulated Deficit	-4,809	-4,717	-4,532	-4,403	-4,223	-4,108	-3,957	-3,823	-3,690	-3,558	-3,388	-3,264
Stockholders Equity	-291	-236	-80	9	151	144	255	347	432	140	275	32
Liabilities And Stockholders Equity	1,264	1,296	1,532	1,190	1,306	1,312	1,503	1,538	1,618	1,307	1,491	1,238
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	-
Preferred Stock Shares Authorized	25	25	25	25	25	25	25	25	25	25	25	25
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	-
Common Stock Shares Authorized	250	250	250	250	250	250	250	250	250	250	250	250
Common Stock Shares Issued	-	-	-	-	-	-	-	-	-	-	-	72
Shares Outstanding	99	98	97	96	96	94	93	92	92	83	82	72
Treasury Stock Common Shares	0	0	0	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-7.67%	18.67%	3.74%	-	-	-	-	-	-	-	-	-
2025	1.83%	9.28%	-18.19%	6.81%	3.67%	19.54%	9.04%	7.28%	-24.04%	4.35%	13.94%	27.73%
2024	-5.64%	-7.37%	-0.47%	12.44%	16.41%	11.47%	-5.72%	-14.05%	-12.81%	-11.18%	-22.92%	-20.73%
2023	-	-	-	-	-	-	0.80%	22.33%	14.86%	-1.68%	-2.45%	-15.11%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	1.73	2.02	2.48	1.89	2.45	2.40	2.38	2.81	3.54	2.43	2.61	2.36
Quick Ratio	1.40	1.64	2.18	1.58	2.09	2.03	2.13	2.65	3.39	2.28	2.32	2.05
Working Capital	255.00M	332.00M	567.00M	303.18M	426.54M	407.49M	473.00M	514.60M	691.77M	350.39M	451.75M	345.21M
Leverage & Debt
Debt to Equity	-5.32	-6.46	-20.06	128.21	7.60	8.06	4.87	3.42	2.74	8.32	4.41	38.04
Debt Ratio	1.22	1.18	1.05	0.99	0.88	0.88	0.83	0.77	0.73	0.89	0.82	0.97
Efficiency & Turnover
Asset Turnover TTM	0.56	0.51	0.44	0.46	0.42	0.45	0.37	0.38	0.33	0.33	0.29	0.29
Days Sales Outstanding TTM	82.59	59.88	75.93	59.57	68.93	61.57	63.68	60.25	66.93	59.07	47.84	49.13
Receivables Turnover TTM	4.42	6.10	4.81	6.13	5.30	5.93	5.73	6.06	5.45	6.18	7.63	7.43
Per Share Metrics
Diluted EPS TTM	-5.75	-6.05	-5.83	-5.81	-5.41	-5.70	-6.29	-5.85	-6.76	-7.28	-8.25	-8.86
Free Cash Flow Per Share TTM	-4.80	-5.00	-4.79	-4.52	-4.34	-4.09	-4.65	-4.47	-5.54	-6.30	-7.06	-7.69
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	83.58%	83.80%	84.59%	85.22%	85.01%	86.25%	83.90%	84.60%	85.82%	-	-
Operating Profit Margin TTM	-73.64%	-83.73%	-79.49%	-86.30%	-82.82%	-87.04%	-95.71%	-102.49%	-114.04%	-131.15%	-131.08%	-144.51%
Net Profit Margin TTM	-81.73%	-90.90%	-85.44%	-91.92%	-87.31%	-93.08%	-101.61%	-106.93%	-121.57%	-138.58%	-139.70%	-154.87%
Growth Metrics
Net Revenue Growth (1Y)	17.51%	13.53%	20.18%	20.63%	26.77%	33.35%	28.96%	27.44%	19.47%	15.29%	19.52%	19.46%
Net Income Growth (1Y)	10.00%	10.87%	1.05%	3.69%	-8.96%	-10.44%	-6.20%	-12.01%	-18.82%	-14.70%	-14.25%	-6.31%
EPS Growth (1Y)	6.33%	6.13%	-7.25%	-0.76%	-19.97%	-21.61%	-23.78%	-33.97%	-33.52%	-28.79%	-18.48%	-8.41%
Valuation Metrics
P/E TTM	-5.81	-3.46	-3.94	-5.18	-6.72	-6.35	-6.69	-9.49	-6.08	-6.42	-5.80	-4.02
P/B TTM	-11.69	-8.93	-28.35	327.67	23.72	24.22	14.93	15.29	8.23	28.06	12.77	80.56
P/S TTM	4.75	3.15	3.37	4.76	5.87	5.91	6.80	10.15	7.39	8.89	8.10	6.23
Market Cap	3.40B	2.11B	2.27B	3.00B	3.58B	3.49B	3.81B	5.30B	3.56B	3.94B	3.52B	2.55B
Enterprise Value	3.28B	1.93B	1.85B	2.80B	3.41B	3.36B	3.63B	5.15B	3.08B	3.82B	3.30B	2.48B
Calculated Values
Free Cash Flow TTM	-489.00M	-503.00M	-472.00M	-450.71M	-427.09M	-394.06M	-421.00M	-427.03M	-479.98M	-531.11M	-519.07M	-550.88M
Net Debt	-125.00M	-175.00M	-421.00M	-202.51M	-176.00M	-127.00M	-174.00M	-150.62M	-480.69M	-112.25M	-213.58M	-72.58M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-15Sale

Owner: Parschauer, Karah Herdman

Title: EVP and Chief Legal Officer

Shares: 1,899

Price/Share: $24.62

Value: $46,753.38

Shares Owned: 94,462

Relationship: Officer

Ownership: Direct

2026-06-15Sale

Owner: Sanders, Corazon (Corsee)…

Title: -

Shares: 2,000

Price/Share: $25.05

Value: $50,100.00

Shares Owned: 21,095

Relationship: Director

Ownership: Direct

2026-06-01Sale

Owner: Horn, Howard

Title: Chief Financial Officer

Shares: 4,653

Price/Share: $23.77

Value: $110,601.81

Shares Owned: 105,689

Relationship: Officer

Ownership: Direct

2026-05-18Sale

Owner: Suliman, Shehnaaz

Title: -

Shares: 5,740

Price/Share: $25.12

Value: $144,188.80

Shares Owned: 27,951

Relationship: Director

Ownership: Direct

2026-05-05Sale

Owner: Crombez, Eric

Title: EVP and Chief Medical Officer

Shares: 344

Price/Share: $24.96

Value: $8,586.24

Shares Owned: 111,189

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-15	Parschauer, Karah Herdman	Officer	EVP and Chief Legal Officer	Direct	Sale	1,899	24.62	$46,753.38	94,462	4
2026-06-15	Sanders, Corazon (Corsee)…	Director	-	Direct	Sale	2,000	25.05	$50,100.00	21,095	4
2026-06-01	Horn, Howard	Officer	Chief Financial Officer	Direct	Sale	4,653	23.77	$110,601.81	105,689	4
2026-05-18	Suliman, Shehnaaz	Director	-	Direct	Sale	5,740	25.12	$144,188.80	27,951	4
2026-05-05	Crombez, Eric	Officer	EVP and Chief Medical Officer	Direct	Sale	344	24.96	$8,586.24	111,189	4
2026-05-01	Horn, Howard	Officer	Chief Financial Officer	Direct	Sale	4,683	24.90	$116,606.70	110,342	4
2026-04-01	Horn, Howard	Officer	Chief Financial Officer	Direct	Sale	4,683	20.97	$98,202.51	80,351	4
2026-03-10	Parschauer, Karah Herdman	Officer	EVP and Chief Legal Officer	Direct	Sale	3,508	22.67	$79,526.36	66,820	4
2026-03-03	Horn, Howard	Officer	Chief Financial Officer	Direct	Sale	1,635	22.40	$36,624.00	85,034	4
2026-03-02	Kakkis, Emil D	Director,Officer	President & CEO	Direct	Sale	54,404	22.80	$1,240,411.20	658,994	4
2026-03-02	Crombez, Eric	Officer	EVP and Chief Medical Officer	Direct	Sale	7,029	22.80	$160,261.20	76,301	4
2026-03-02	Pinion, John Richard	Officer	See Remarks	Direct	Sale	10,029	22.80	$228,661.20	110,026	4
2026-03-02	Harris, Erik	Officer	EVP & Chief Commercial Officer	Direct	Sale	10,539	22.80	$240,289.20	89,515	4
2026-03-02	Huizenga, Theodore Alan	Officer	SVP, Chief Accounting Officer	Direct	Sale	1,632	22.80	$37,209.60	48,670	4
2026-03-02	Parschauer, Karah Herdman	Officer	EVP and Chief Legal Officer	Direct	Sale	8,135	22.80	$185,478.00	76,346	4
2026-02-02	Horn, Howard	Officer	Chief Financial Officer	Direct	Sale	3,061	23.56	$72,117.16	88,935	4
2026-01-02	Horn, Howard	Officer	Chief Financial Officer	Direct	Sale	3,150	22.84	$71,946.00	91,996	4
2025-12-29	Huizenga, Theodore Alan	Officer	SVP, Chief Accounting Officer	Direct	Sale	85	34.38	$2,922.30	50,450	4
2025-12-10	Horn, Howard	Officer	Chief Financial Officer	Direct	Sale	3,081	36.38	$112,086.78	95,146	4
2025-10-13	Horn, Howard	Officer	Chief Financial Officer	Direct	Sale	7,942	31.51	$250,252.42	98,227	4
2025-09-18	Huizenga, Theodore Alan	Officer	SVP, Chief Accounting Officer	Direct	Sale	64	29.17	$1,866.88	50,242	4
2025-09-12	Parschauer, Karah Herdman	Officer	EVP and Chief Legal Officer	Direct	Sale	2,450	31.17	$76,366.50	73,271	4
2025-09-05	Huizenga, Theodore Alan	Officer	SVP, Chief Accounting Officer	Direct	Sale	84	31.39	$2,636.76	50,306	4
2025-06-20	Sanders, Corazon (Corsee)…	Director	-	Direct	Sale	2,405	37.39	$89,922.95	15,344	4
2025-05-05	Crombez, Eric	Officer	EVP and Chief Medical Officer	Direct	Sale	520	39.24	$20,404.80	71,530	4
2025-03-06	Horn, Howard	Officer	Chief Financial Officer	Direct	Sale	1,785	40.40	$72,114.00	106,169	4
2025-03-03	Pinion, John Richard	Officer	See Remarks	Direct	Sale	14,439	42.10	$607,881.90	107,766	4
2025-03-03	Crombez, Eric	Officer	EVP and Chief Medical Officer	Direct	Sale	8,945	42.10	$376,584.50	71,922	4
2025-03-03	Kassberg, Thomas Richard	Officer	CBO & EVP	Direct	Sale	6,028	42.10	$253,778.80	265,238	4
2025-03-03	Parschauer, Karah Herdman	Officer	EVP and Chief Legal Officer	Direct	Sale	12,846	42.10	$540,816.60	75,287	4
2025-03-03	Huizenga, Theodore Alan	Officer	SVP, Chief Accounting Officer	Direct	Sale	967	42.10	$40,710.70	50,265	4
2025-03-03	Kakkis, Emil D	Director,Officer	President & CEO	Direct	Sale	73,434	42.10	$3,091,571.40	641,731	4
2025-03-03	Harris, Erik	Officer	EVP & Chief Commercial Officer	Direct	Sale	15,103	42.10	$635,836.30	87,855	4
2025-02-27	Parschauer, Karah Herdman	Officer	EVP and Chief Legal Officer	Direct	Sale	2,990	42.84	$128,091.60	54,991	4
2024-12-30	Kakkis, Emil D	Director,Officer	President & CEO	Indirect	Sale	11,727	42.23	$495,231.21	2,183,985	4
2024-12-10	Kakkis, Emil D	Director,Officer	President & CEO	Indirect	Sale	8,273	50.00	$413,650.00	2,195,712	4
2024-10-10	Horn, Howard	Officer	Chief Financial Officer	Direct	Sale	7,465	52.76	$393,853.40	92,301	4
2024-09-03	Kakkis, Emil D	Director,Officer	President & CEO	Indirect	Sale	20,000	55.85	$1,117,000.00	2,223,985	4
2024-09-03	Huizenga, Theodore Alan	Officer	SVP, Chief Accounting Officer	Direct	Sale	91	56.19	$5,113.29	41,551	4
2024-08-06	Kakkis, Emil D	Director,Officer	President & CEO	Indirect	Sale	20,000	50.17	$1,003,400.00	2,243,985	4
2024-07-02	Sanders, Corazon (Corsee)…	Director	-	Direct	Sale	584	40.98	$23,932.32	12,009	4
2024-06-12	Parschauer, Karah Herdman	Officer	EVP and Chief Legal Officer	Direct	Sale	9,806	45.00	$441,270.00	57,981	4
2024-06-10	Sanders, Corazon (Corsee)…	Director	-	Direct	Sale	1,737	41.10	$71,390.70	7,248	4
2024-05-02	Crombez, Eric	Officer	EVP and Chief Medical Officer	Direct	Sale	354	43.66	$15,455.64	48,431	4
2024-04-18	Crombez, Eric	Officer	EVP and Chief Medical Officer	Direct	Sale	142	44.10	$6,262.20	48,785	4
2024-03-11	Kassberg, Thomas Richard	Officer	CBO & EVP	Direct	Sale	11,509	49.93	$574,644.37	252,823	4
2024-03-07	Fust, Matthew K	Director	-	Direct	Sale	12,195	50.87	$620,359.65	14,860	4
2024-03-01	Pinion, John Richard	Officer	See Remarks	Direct	Sale	4,173	53.76	$224,340.48	89,268	4
2024-03-01	Huizenga, Theodore Alan	Officer	SVP, Chief Accounting Officer	Direct	Sale	341	53.76	$18,332.16	41,380	4
2024-03-01	Harris, Erik	Officer	EVP & Chief Commercial Officer	Direct	Sale	4,768	53.76	$256,327.68	67,163	4
2024-03-01	Kassberg, Thomas Richard	Officer	CBO & EVP	Direct	Sale	1,011	53.76	$54,351.36	264,332	4
2024-03-01	Parschauer, Karah Herdman	Officer	EVP and Chief Legal Officer	Direct	Sale	3,756	53.76	$201,922.56	67,340	4
2024-03-01	Crombez, Eric	Officer	EVP and Chief Medical Officer	Direct	Sale	1,238	53.76	$66,554.88	48,927	4
2024-02-07	Kakkis, Emil D	Director,Officer	President & CEO	Direct	Sale	30,000	45.00	$1,350,000.00	539,770	4
2023-12-29	Kakkis, Emil D	Director,Officer	President & CEO	Direct	Sale	30,000	47.87	$1,436,100.00	569,770	4
2023-10-23	Kassberg, Thomas Richard	Officer	CBO & EVP	Direct	Sale	39,878	32.78	$1,307,200.84	246,860	4
2023-10-19	Kakkis, Emil D	Director,Officer	President & CEO	Direct	Sale	47,853	33.52	$1,604,032.56	599,743	4
2023-09-07	Huizenga, Theodore Alan	Officer	SVP, Chief Accounting Officer	Direct	Sale	2,163	39.67	$85,806.21	23,614	4
2023-09-05	Harris, Erik	Officer	EVP & Chief Commercial Officer	Direct	Sale	6,000	37.96	$227,760.00	51,281	4
2023-09-01	Huizenga, Theodore Alan	Officer	SVP, Chief Accounting Officer	Direct	Sale	970	37.64	$36,510.80	23,777	4
2023-06-30	Sanders, Corazon (Corsee)…	Director	-	Direct	Sale	585	46.76	$27,354.60	8,985	4
2023-06-19	Harris, Erik	Officer	EVP & Chief Commercial Officer	Direct	Sale	305	48.20	$14,701.00	57,281	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

93.01%

Inst. Shares: 93,566,809

Shares Outstanding: 100,600,000

2025-12-31

89.22%

Inst. Shares: 87,970,143

Shares Outstanding: 98,600,000

2025-09-30

89.90%

Inst. Shares: 89,693,123

Shares Outstanding: 99,771,297

2025-06-30

90.12%

Inst. Shares: 88,734,634

Shares Outstanding: 98,460,445

2025-03-31

85.49%

Inst. Shares: 82,329,100

Shares Outstanding: 96,300,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	93,566,809	100,600,000	93.01%
2025-12-31	87,970,143	98,600,000	89.22%
2025-09-30	89,693,123	99,771,297	89.90%
2025-06-30	88,734,634	98,460,445	90.12%
2025-03-31	82,329,100	96,300,000	85.49%
2024-12-31	82,644,283	90,500,000	91.32%
2024-09-30	80,953,741	95,493,996	84.77%
2024-06-30	83,495,513	86,580,516	96.44%
2024-03-31	74,189,224	84,286,292	88.02%
2023-12-31	75,142,556	73,543,862	102.17%
2023-09-30	66,075,886	71,664,493	92.20%
2023-06-30	64,242,297	70,897,991	90.61%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Ultragenyx Pharmaceutical Inc. (RARE) — SEC Financial Statements & Analysis

Ultragenyx Pharmaceutical Inc. (RARE) is a pharmaceutical preparations company, incorporated in DE. Ultragenyx Pharmaceutical Inc. trades on Nasdaq as: RARE. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Ultragenyx Pharmaceutical Inc. reported a 17.51% year-over-year revenue growth, a Gross Profit Margin of 83.58% (TTM), a Debt-to-Equity ratio of -5.32x, a Price-to-Sales (P/S) ratio of 4.75x (TTM), a Price-to-Book (P/B) ratio of -11.69x (TTM), at a market cap of $3.40B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 17.51%
Gross Profit Margin TTM: 83.58%
Debt To Equity: -5.32x
P/S TTM: 4.75x
P/B TTM: -11.69x
Market Cap: $3.40B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Ultragenyx Pharmaceutical Inc. in?

Ultragenyx Pharmaceutical Inc. (RARE) operates in the Pharmaceutical Preparations industry.

What is RARE's market cap?

Ultragenyx Pharmaceutical Inc. (RARE) has a market capitalization of $3.40B as of 2026-06-30.

What exchange does RARE trade on?

Ultragenyx Pharmaceutical Inc. (RARE) trades on the Nasdaq.

Where is Ultragenyx Pharmaceutical Inc. incorporated?

Ultragenyx Pharmaceutical Inc. is incorporated in DE.